NASDAQ:STAA

STAAR Surgical Competitors

$124.76
+2.76 (+2.26 %)
(As of 05/5/2021 12:00 AM ET)
Add
Compare
Today's Range
$121.17
$127.75
50-Day Range
$91.66
$139.16
52-Week Range
$34.41
$139.97
Volume934,968 shs
Average Volume734,401 shs
Market Capitalization$5.85 billion
P/E Ratio656.67
Dividend YieldN/A
Beta1.09

Competitors

STAAR Surgical (NASDAQ:STAA) Vs. ALGN, WST, COO, XRAY, NEOG, and QDEL

Should you be buying STAA stock or one of its competitors? Companies in the sub-industry of "health care supplies" are considered alternatives and competitors to STAAR Surgical, including Align Technology (ALGN), West Pharmaceutical Services (WST), The Cooper Companies (COO), DENTSPLY SIRONA (XRAY), Neogen (NEOG), and Quidel (QDEL).

Align Technology (NASDAQ:ALGN) and STAAR Surgical (NASDAQ:STAA) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, dividends, profitability, analyst recommendations, valuation, risk and institutional ownership.

Valuation & Earnings

This table compares Align Technology and STAAR Surgical's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Align Technology$2.41 billion18.72$442.78 million$4.96114.77
STAAR Surgical$150.18 million38.96$14.05 million$0.46271.22

Align Technology has higher revenue and earnings than STAAR Surgical. Align Technology is trading at a lower price-to-earnings ratio than STAAR Surgical, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

85.8% of Align Technology shares are held by institutional investors. Comparatively, 85.4% of STAAR Surgical shares are held by institutional investors. 1.2% of Align Technology shares are held by company insiders. Comparatively, 3.9% of STAAR Surgical shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Align Technology and STAAR Surgical, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Align Technology111002.75
STAAR Surgical03302.50

Align Technology currently has a consensus price target of $627.0909, indicating a potential upside of 10.16%. STAAR Surgical has a consensus price target of $68.50, indicating a potential downside of 45.09%. Given Align Technology's stronger consensus rating and higher possible upside, analysts clearly believe Align Technology is more favorable than STAAR Surgical.

Profitability

This table compares Align Technology and STAAR Surgical's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Align Technology76.00%68.99%46.64%
STAAR Surgical5.73%8.99%7.12%

Risk & Volatility

Align Technology has a beta of 1.68, indicating that its stock price is 68% more volatile than the S&P 500. Comparatively, STAAR Surgical has a beta of 1.09, indicating that its stock price is 9% more volatile than the S&P 500.

Summary

Align Technology beats STAAR Surgical on 11 of the 14 factors compared between the two stocks.

STAAR Surgical (NASDAQ:STAA) and West Pharmaceutical Services (NYSE:WST) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, valuation, dividends, institutional ownership, earnings, risk and analyst recommendations.

Valuation & Earnings

This table compares STAAR Surgical and West Pharmaceutical Services' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
STAAR Surgical$150.18 million38.96$14.05 million$0.46271.22
West Pharmaceutical Services$1.84 billion13.19$241.70 million$3.24101.42

West Pharmaceutical Services has higher revenue and earnings than STAAR Surgical. West Pharmaceutical Services is trading at a lower price-to-earnings ratio than STAAR Surgical, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

85.4% of STAAR Surgical shares are held by institutional investors. Comparatively, 92.6% of West Pharmaceutical Services shares are held by institutional investors. 3.9% of STAAR Surgical shares are held by insiders. Comparatively, 1.6% of West Pharmaceutical Services shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Volatility and Risk

STAAR Surgical has a beta of 1.09, suggesting that its stock price is 9% more volatile than the S&P 500. Comparatively, West Pharmaceutical Services has a beta of 1.13, suggesting that its stock price is 13% more volatile than the S&P 500.

Analyst Ratings

This is a summary of current recommendations and price targets for STAAR Surgical and West Pharmaceutical Services, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
STAAR Surgical03302.50
West Pharmaceutical Services01202.67

STAAR Surgical presently has a consensus target price of $68.50, suggesting a potential downside of 45.09%. West Pharmaceutical Services has a consensus target price of $310.00, suggesting a potential downside of 5.66%. Given West Pharmaceutical Services' stronger consensus rating and higher probable upside, analysts plainly believe West Pharmaceutical Services is more favorable than STAAR Surgical.

Profitability

This table compares STAAR Surgical and West Pharmaceutical Services' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
STAAR Surgical5.73%8.99%7.12%
West Pharmaceutical Services14.69%19.01%12.78%

Summary

West Pharmaceutical Services beats STAAR Surgical on 10 of the 14 factors compared between the two stocks.

The Cooper Companies (NYSE:COO) and STAAR Surgical (NASDAQ:STAA) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, earnings, analyst recommendations, profitability, institutional ownership, valuation and risk.

Profitability

This table compares The Cooper Companies and STAAR Surgical's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
The Cooper Companies9.81%12.79%7.20%
STAAR Surgical5.73%8.99%7.12%

Insider and Institutional Ownership

95.8% of The Cooper Companies shares are owned by institutional investors. Comparatively, 85.4% of STAAR Surgical shares are owned by institutional investors. 1.4% of The Cooper Companies shares are owned by insiders. Comparatively, 3.9% of STAAR Surgical shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Analyst Ratings

This is a breakdown of current recommendations for The Cooper Companies and STAAR Surgical, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
The Cooper Companies04702.64
STAAR Surgical03302.50

The Cooper Companies currently has a consensus target price of $385.50, indicating a potential downside of 3.84%. STAAR Surgical has a consensus target price of $68.50, indicating a potential downside of 45.09%. Given The Cooper Companies' stronger consensus rating and higher probable upside, research analysts clearly believe The Cooper Companies is more favorable than STAAR Surgical.

Valuation & Earnings

This table compares The Cooper Companies and STAAR Surgical's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
The Cooper Companies$2.43 billion8.11$238.40 million$9.6441.59
STAAR Surgical$150.18 million38.96$14.05 million$0.46271.22

The Cooper Companies has higher revenue and earnings than STAAR Surgical. The Cooper Companies is trading at a lower price-to-earnings ratio than STAAR Surgical, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

The Cooper Companies has a beta of 0.82, indicating that its share price is 18% less volatile than the S&P 500. Comparatively, STAAR Surgical has a beta of 1.09, indicating that its share price is 9% more volatile than the S&P 500.

Summary

The Cooper Companies beats STAAR Surgical on 10 of the 14 factors compared between the two stocks.

STAAR Surgical (NASDAQ:STAA) and DENTSPLY SIRONA (NASDAQ:XRAY) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, dividends, earnings, analyst recommendations, profitability, institutional ownership and risk.

Analyst Ratings

This is a summary of recent ratings and price targets for STAAR Surgical and DENTSPLY SIRONA, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
STAAR Surgical03302.50
DENTSPLY SIRONA15602.42

STAAR Surgical presently has a consensus target price of $68.50, suggesting a potential downside of 45.09%. DENTSPLY SIRONA has a consensus target price of $55.8182, suggesting a potential downside of 17.42%. Given DENTSPLY SIRONA's higher probable upside, analysts clearly believe DENTSPLY SIRONA is more favorable than STAAR Surgical.

Institutional & Insider Ownership

85.4% of STAAR Surgical shares are owned by institutional investors. Comparatively, 96.0% of DENTSPLY SIRONA shares are owned by institutional investors. 3.9% of STAAR Surgical shares are owned by insiders. Comparatively, 0.5% of DENTSPLY SIRONA shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Risk & Volatility

STAAR Surgical has a beta of 1.09, suggesting that its share price is 9% more volatile than the S&P 500. Comparatively, DENTSPLY SIRONA has a beta of 0.98, suggesting that its share price is 2% less volatile than the S&P 500.

Profitability

This table compares STAAR Surgical and DENTSPLY SIRONA's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
STAAR Surgical5.73%8.99%7.12%
DENTSPLY SIRONA-1.40%7.13%4.13%

Valuation & Earnings

This table compares STAAR Surgical and DENTSPLY SIRONA's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
STAAR Surgical$150.18 million38.96$14.05 million$0.46271.22
DENTSPLY SIRONA$4.03 billion3.66$262.90 million$2.4527.59

DENTSPLY SIRONA has higher revenue and earnings than STAAR Surgical. DENTSPLY SIRONA is trading at a lower price-to-earnings ratio than STAAR Surgical, indicating that it is currently the more affordable of the two stocks.

Summary

STAAR Surgical beats DENTSPLY SIRONA on 8 of the 14 factors compared between the two stocks.

Neogen (NASDAQ:NEOG) and STAAR Surgical (NASDAQ:STAA) are both mid-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, profitability, analyst recommendations, institutional ownership, earnings, valuation and dividends.

Profitability

This table compares Neogen and STAAR Surgical's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Neogen13.92%8.13%7.45%
STAAR Surgical5.73%8.99%7.12%

Valuation and Earnings

This table compares Neogen and STAAR Surgical's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Neogen$418.17 million11.97$59.47 million$1.1382.80
STAAR Surgical$150.18 million38.96$14.05 million$0.46271.22

Neogen has higher revenue and earnings than STAAR Surgical. Neogen is trading at a lower price-to-earnings ratio than STAAR Surgical, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings and recommmendations for Neogen and STAAR Surgical, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Neogen02102.33
STAAR Surgical03302.50

Neogen presently has a consensus price target of $81.50, suggesting a potential downside of 12.89%. STAAR Surgical has a consensus price target of $68.50, suggesting a potential downside of 45.09%. Given Neogen's higher probable upside, equities analysts clearly believe Neogen is more favorable than STAAR Surgical.

Volatility and Risk

Neogen has a beta of 0.5, meaning that its stock price is 50% less volatile than the S&P 500. Comparatively, STAAR Surgical has a beta of 1.09, meaning that its stock price is 9% more volatile than the S&P 500.

Institutional & Insider Ownership

92.8% of Neogen shares are owned by institutional investors. Comparatively, 85.4% of STAAR Surgical shares are owned by institutional investors. 0.9% of Neogen shares are owned by company insiders. Comparatively, 3.9% of STAAR Surgical shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Quidel (NASDAQ:QDEL) and STAAR Surgical (NASDAQ:STAA) are both mid-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, profitability, valuation, analyst recommendations, institutional ownership, earnings and risk.

Institutional and Insider Ownership

84.0% of Quidel shares are owned by institutional investors. Comparatively, 85.4% of STAAR Surgical shares are owned by institutional investors. 14.1% of Quidel shares are owned by insiders. Comparatively, 3.9% of STAAR Surgical shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current recommendations for Quidel and STAAR Surgical, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Quidel10302.50
STAAR Surgical03302.50

Quidel currently has a consensus price target of $189.00, suggesting a potential upside of 68.00%. STAAR Surgical has a consensus price target of $68.50, suggesting a potential downside of 45.09%. Given Quidel's higher probable upside, research analysts plainly believe Quidel is more favorable than STAAR Surgical.

Profitability

This table compares Quidel and STAAR Surgical's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Quidel36.91%63.31%40.55%
STAAR Surgical5.73%8.99%7.12%

Valuation & Earnings

This table compares Quidel and STAAR Surgical's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Quidel$534.89 million8.95$72.92 million$2.7341.21
STAAR Surgical$150.18 million38.96$14.05 million$0.46271.22

Quidel has higher revenue and earnings than STAAR Surgical. Quidel is trading at a lower price-to-earnings ratio than STAAR Surgical, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Quidel has a beta of 0.45, meaning that its stock price is 55% less volatile than the S&P 500. Comparatively, STAAR Surgical has a beta of 1.09, meaning that its stock price is 9% more volatile than the S&P 500.

Summary

Quidel beats STAAR Surgical on 8 of the 12 factors compared between the two stocks.


STAAR Surgical Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Align Technology logo
ALGN
Align Technology
2.1$569.25+2.3%$45.05 billion$2.41 billion25.90Analyst Report
West Pharmaceutical Services logo
WST
West Pharmaceutical Services
1.9$328.60+0.2%$24.27 billion$1.84 billion86.70Earnings Announcement
Analyst Revision
The Cooper Companies logo
COO
The Cooper Companies
1.9$400.88+2.7%$19.70 billion$2.43 billion83.34Analyst Report
DENTSPLY SIRONA logo
XRAY
DENTSPLY SIRONA
2.0$67.59+2.0%$14.75 billion$4.03 billion-293.87Unusual Options Activity
Neogen logo
NEOG
Neogen
1.2$93.56+1.6%$5.01 billion$418.17 million82.07
Quidel logo
QDEL
Quidel
2.4$112.50+2.2%$4.79 billion$534.89 million13.20
ICU Medical logo
ICUI
ICU Medical
1.5$210.30+1.6%$4.46 billion$1.27 billion55.64Insider Selling
Merit Medical Systems logo
MMSI
Merit Medical Systems
1.5$63.64+1.5%$3.54 billion$994.85 million-120.07Earnings Announcement
Analyst Revision
Haemonetics logo
HAE
Haemonetics
2.1$62.10+2.3%$3.16 billion$988.48 million30.00Upcoming Earnings
Increase in Short Interest
Atrion logo
ATRI
Atrion
1.1$601.52+1.9%$1.10 billion$155.07 million33.89
Cerus logo
CERS
Cerus
1.7$6.02+7.0%$1.03 billion$74.65 million-15.44Earnings Announcement
Unusual Options Activity
News Coverage
Gap Up
Meridian Bioscience logo
VIVO
Meridian Bioscience
1.7$19.24+0.6%$830.11 million$253.67 million17.81Upcoming Earnings
OraSure Technologies logo
OSUR
OraSure Technologies
1.7$9.02+2.8%$648.95 million$154.60 million-39.22Earnings Announcement
News Coverage
Antares Pharma logo
ATRS
Antares Pharma
1.8$3.79+1.1%$639.74 million$123.86 million63.18Analyst Upgrade
Anika Therapeutics logo
ANIK
Anika Therapeutics
1.5$41.43+1.7%$595.23 million$114.51 million-88.15
Utah Medical Products logo
UTMD
Utah Medical Products
0.9$87.85+0.7%$320.30 million$46.90 million27.71
This page was last updated on 5/6/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.